Description: Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Home Page: www.xenon-pharma.com
3650 Gilmore Way
Burnaby,
BC
V5G 4W8
Canada
Phone:
604 484 3300
Officers
| Name | Title |
|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director |
| Ms. Sherry Aulin C.A., CPA | Chief Financial Officer |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Ms. Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of R&D Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.945 |
| Price-to-Sales TTM: | 171.8999 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 251 |